Current Edition


Heptares and ICL sign gastrointestinal R&D pact

Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on …

Continue Reading →

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal and inflammatory diseases and cancer, …

Continue Reading →